Free Trial

Enliven Therapeutics (ELVN) SEC Filings & 10K Form

Enliven Therapeutics logo
$21.91 +2.25 (+11.44%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$21.96 +0.05 (+0.25%)
As of 06/13/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Enliven Therapeutics SEC Filings

DateFilerForm TypeView
06/13/2025
5:17 AM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 424B5
06/13/2025
5:26 AM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form S-3MEF
06/13/2025
5:05 AM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2025
5:25 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025
3:21 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2025
3:53 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:55 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025
4:34 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2025
4:14 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/29/2025
4:38 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025
5:29 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025
5:31 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
3:21 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2025
3:22 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2025
5:48 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025
5:42 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025
5:43 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/30/2025
5:59 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2025
3:08 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form DEFA14A
04/28/2025
3:12 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form ARS
04/21/2025
4:55 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2025
3:25 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2025
3:09 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2025
6:37 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2025
3:01 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/26/2025
6:37 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/21/2025
4:49 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2025
4:42 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2025
3:18 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/18/2025
4:33 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144/A
03/18/2025
4:22 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144/A
03/18/2025
3:06 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/17/2025
3:14 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2025
4:05 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/07/2025
3:18 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2025
5:02 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
7:07 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2025
3:10 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
4:02 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
2:45 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Fairmount Funds Management LLC (Filed by)
Form SCHEDULE 13G/A
02/14/2025
8:17 AM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SCHEDULE 13G/A
[Wanted] 250 intrepid souls (Ad)

He Called this 106X Opportunity Before Reddit… and Before Elon Musk Before GameStop rocketed up to 10,633, Jonathan Rose saw something strange: A sudden surge in options volume — thousands of contracts flooding in. The money hit deep inside the CBOE before Reddit posts created the short squeeze and before Elon's tweet sent GameStop flying. Jonathan calls it the "Big-Money Tell," and it's flagged dozens of big trade opportunities including: 462.5% in C3.ai, 245.13% in Criteo, and 39.46% in Roku. And these are just some of the gains the "tell" has identified. Even better: He says the next big set-up could be forming right now. And there's still time for you to get in before it kicks off as soon as seven days from now.

Click here for the details from Jonathan himself.
02/10/2025
4:36 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Gupta Rishi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:38 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:39 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kunkel Lori Anne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:40 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Phillips Andrew John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:25 PM
Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:27 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:28 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:29 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:32 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:33 PM
Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:34 PM
Bauer Jake (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:35 PM
Derynck Mika K (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
6:06 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/29/2025
6:21 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:37 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/14/2025
3:06 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/14/2025
3:01 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/10/2025
4:31 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:43 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:21 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/31/2024
4:18 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
3:33 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2024
3:15 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
4:18 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/15/2024
3:28 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
4:46 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G/A
11/14/2024
4:48 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
Form SC 13G/A
11/14/2024
3:24 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G/A
11/13/2024
4:55 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SC 13G
11/13/2024
3:15 PM
Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/08/2024
1:17 PM
BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G
10/30/2024
5:04 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2024
1:02 PM
BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G
10/22/2024
3:18 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:19 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:21 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:22 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:23 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:17 PM
Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
5:42 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:27 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:42 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:10 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:17 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:57 PM
Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:00 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
4:06 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
3:38 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/10/2024
7:36 PM
Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2024
7:38 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
The End of Elon Musk…? (Ad)

The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.

Click here to see why the "End of Elon" crowd is about to be wrong again.
10/10/2024
7:39 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2024
3:27 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/09/2024
3:16 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/08/2024
5:54 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
5:56 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
5:57 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
5:58 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2024
3:28 PM
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/03/2024
5:43 PM
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners